English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The FDA has approved tazemetostat for treating epithelioid sarcoma. The drug produced responses in 15% of patients with the disease in a phase II trial, and 67% of the responses lasted at least 6 months. The drug is the first targeted treatment for epithelioid sarcoma.

First EZH2 Inhibitor Approved—for Rare Sarcoma